RE:RE:RE:RE:TauRx delayed meeting - Slam dunk ?
Hi FrozenInOntario.
"Liiy and Novartis that have Alzheimer drugs, as well as Esai are participating as comparators companies"
I saw that on the list a few months ago. And that is my point. Large pharmaceutical companies know about TauRx, yet none have moved to get control or a large position.
At this point TauRx is valued at about $3 to 4 billion US dollars. While I do not expect TauRx to get approval this year, if it were approved, the word in Asia brings the value to US$20 to $30 billions.
These large outfits would rather invest on the basis of $3 to 4 billion if they see a real potential. Since they don't, neither do I.
I realize some may have a more optimistic view on TauRx. That is why I have suggested some time ago that Dundee should simply divest on its TauRx holdings (about one million shares) to Dundee shareholders.
Those who do not believe in TauRx could sell their holdings while those willing to invest in TauRx could buy their positions.
Everybody wins including management who would no longer have to be concerned with TauRx and use their time and talent exclusively on Dundee 2.0 (mineral exploration)!